Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

The Novel Protein HSF1 Stress Pathway Inhibitor Bisamide CCT361814 Demonstrates Pre-Clinical Anti-Tumor Activity in Myeloma

Karen Menezes, PhD BSc, MSc, Grace Aram, MSc, Fabio Mirabella, PhD, David C Johnson, PhD, Amy L Sherborne, PhD, Richard S Houlston, MD PhD, Matthew D Cheeseman, PhD, Elisa Pasqua, PhD, Paul Clarke, PhD, Paul Workman, PhD, Keith Jones, PhD, Martin F Kaiser, MD

Blood (2017) 130 (Supplement 1): 3072.

https://doi.org/10.1182/blood.V130.Suppl_1.3072.3072

Published: 2017

Journal Articles

Inhibition of the Epigenetic Modifier EZH2 Upregulates Cell Cycle Control Genes to Inhibit Myeloma Cell Growth and Overcome High-Risk Disease Features

Charlotte Pawlyn, MB BChir, Michael Bright, PhD, Amy Buros, PhD, Caleb K. Stein, MS, Zoe Walters, PhD, Lauren Aronson, PhD, Fabio Mirabella, PhD, Martin F Kaiser, MD, John R Jones, MD, Brian A Walker, PhD, Graham H Jackson, MD PhD, Paul Clarke, PhD, Leif Bergsagel, MD, Paul Workman, PhD, Marta Chesi, PhD, Gareth J Morgan, MD PhD, Faith E Davies, MD

Blood (2016) 128 (22): 3289.

https://doi.org/10.1182/blood.V128.22.3289.3289

Published: 2016

Journal Articles

Resistance to Selective FLT3 Inhibitors, Driven by FLT3 Ligand and FLT3 Point Mutations, Can Be Overcome with the Dual FLT3-Aurora Kinase Inhibitor CCT241736,

Andrew S. Moore, MBBS, FRACP, Amir Faisal, Vassilios Bavetsias, David Gonzalez de Castro, PhD, Chongbo Sun, Butrus Atrash, Melanie Valenti, Alexis de Haven Brandon, Sian Avery, Andrew DJ Pearson, Paul Workman, Julian Blagg, Florence I Raynaud, Suzanne A Eccles, Spiros Linardopoulos

Blood (2011) 118 (21): 3492.

https://doi.org/10.1182/blood.V118.21.3492.3492

Published: 2011

Journal Articles

Dual Inhibition of Aurora and FLT3 Kinases by CCT137690: A Novel Treatment Strategy Against FLT3 -ITD Positive AML In Vitro and In Vivo

Andrew S Moore, Amir Faisal, Vassilios Bavetsias, Chongbo Sun, Butrus Atrash, Melanie Valenti, Alexis de Haven Brandon, Sian Avery, Florence I Raynaud, Paul Workman, Andrew DJ Pearson, Julian Blagg, Suzanne A Eccles, Spiros Linardopoulos

Blood (2010) 116 (21): 3289.

https://doi.org/10.1182/blood.V116.21.3289.3289

Published: 2010

Journal Articles

Inhibitors of Heat Shock Protein 72 Induction Enhance Apoptosis Induced by Hsp90 Inhibitors

Emma Davenport, PhD, Athanasia Zeisig, PhD, Lauren Wiseglass, Hannah E. Moore, Sarah L. Hockley, PhD, David Gonzalez, PhD, Emma Smith, PhD, Swee Sharp, PhD, Paul Workman, PhD, Gareth J Morgan, MD.PhD., Faith Davies, MD

Blood (2008) 112 (11): 2625.

https://doi.org/10.1182/blood.V112.11.2625.2625

Published: 2008

Journal Articles

Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells

Emma L. Davenport, Hannah E. Moore, Alan S. Dunlop, Swee Y. Sharp, Paul Workman, Gareth J. Morgan, Faith E. Davies

Blood (2007) 110 (7): 2641–2649.

https://doi.org/10.1182/blood-2006-11-053728

Published: 2007

Includes: Supplemental data

Journal Articles

Hsp90 Inhibitors Deliver a Death Signal Via the Endoplasmic Reticulum Stress Pathway in Myeloma.

Emma L. Davenport, PhD, Hannah Moore, BSc, Alan Dunlop, BSc, Paul Workman, PhD, Gareth J. Morgan, MD, PhD, Faith E. Davies, MD

Blood (2006) 108 (11): 848.

https://doi.org/10.1182/blood.V108.11.848.848

Published: 2006

NARROW

The Novel Protein HSF1 Stress Pathway Inhibitor Bisamide CCT361814 Demonstrates Pre-Clinical Anti-Tumor Activity in Myeloma

Inhibition of the Epigenetic Modifier EZH2 Upregulates Cell Cycle Control Genes to Inhibit Myeloma Cell Growth and Overcome High-Risk Disease Features

Resistance to Selective FLT3 Inhibitors, Driven by FLT3 Ligand and FLT3 Point Mutations, Can Be Overcome with the Dual FLT3-Aurora Kinase Inhibitor CCT241736,

Dual Inhibition of Aurora and FLT3 Kinases by CCT137690: A Novel Treatment Strategy Against FLT3 -ITD Positive AML In Vitro and In Vivo

Inhibitors of Heat Shock Protein 72 Induction Enhance Apoptosis Induced by Hsp90 Inhibitors

Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells

Hsp90 Inhibitors Deliver a Death Signal Via the Endoplasmic Reticulum Stress Pathway in Myeloma.

Email alerts

ASH Publications

American Society of Hematology

The Novel Protein HSF1 Stress Pathway Inhibitor Bisamide CCT361814 Demonstrates Pre-Clinical Anti-Tumor Activity in Myeloma

Inhibition of the Epigenetic Modifier EZH2 Upregulates Cell Cycle Control Genes to Inhibit Myeloma Cell Growth and Overcome High-Risk Disease Features

Resistance to Selective FLT3 Inhibitors, Driven by FLT3 Ligand and FLT3 Point Mutations, Can Be Overcome with the Dual FLT3-Aurora Kinase Inhibitor CCT241736,

Dual Inhibition of Aurora and FLT3 Kinases by CCT137690: A Novel Treatment Strategy Against FLT3 -ITD Positive AML In Vitro and In Vivo

Inhibitors of Heat Shock Protein 72 Induction Enhance Apoptosis Induced by Hsp90 Inhibitors

Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells

Hsp90 Inhibitors Deliver a Death Signal Via the Endoplasmic Reticulum Stress Pathway in Myeloma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only